PDGFRB and cholangiocarcinoma: Notably, therapeutic targeting of the PDGFR-β (imatinib mesylate) [76] might interfere with the interplay of CAFs-CCA cells, whereas small molecule pro-apoptotic compounds, so called BH-3 mimetic, inhibit the BCL-2 protein [54], inducing apoptosis selectively depleting CAFs.